COLL - Why Collegium Pharmaceutical Shares Are Gaining Today | Benzinga
Collegium Pharmaceutical, Inc. (NASDAQ: COLL) today announced FY24 financial guidance and provided a business update.
COLL expects FY24 Product revenues of $580 million-$595 million versus a consensus of $581.19 million.
The company sees Adjusted operating expenses in the range of $120 million-$125 million and Adjusted EBITDA (excluding stock-based compensation) of $380 million-$395 million.
"2023 was a banner ...